Exenatide

Overview

Exenatide (Bydureon®, Byetta®) is a glucagon-like peptide-1 (GLP-1) receptor agonist used in feline medicine as an adjunctive therapy for diabetes mellitus. It is administered subcutaneously and is combined with insulin therapy and dietary management rather than used as a sole treatment.

In diabetic cats, exenatide has been investigated for improving glycemic control, reducing glucose variability, supporting endogenous insulin secretion, and potentially increasing diabetic remission rates when used alongside glargine insulin. Clinical response may vary between individual cats, and current veterinary evidence remains limited.

Mechanism of Action (MOA): Exenatide mimics endogenous incretin hormones by activating GLP-1 receptors. This enhances glucose-dependent insulin secretion, inhibits glucagon secretion without impeding the glucagon response to hypoglycemia, supports pancreatic beta-cell proliferation and survival, improves insulin sensitivity in muscle, reduces hepatic gluconeogenesis, delays gastric emptying and may promote satiety. Because its insulinotropic effect is glucose-dependent, the risk of hypoglycemia is relatively low unless combined with insulin or other hypoglycemic drugs.

Exenatide is available as immediate-release (IR) and extended-release (ER) formulations. These products are not interchangeable and use different dosing schedules.

Indications

Exenatide is primarily used in cats as an adjunctive medication for management of diabetes mellitus. It is not a replacement for insulin therapy and is incorporated into multimodal diabetic treatment plans that include insulin administration, nutritional control and regular glucose monitoring.

• Adjunctive treatment of feline diabetes mellitus: Used with insulin therapy to help improve glycemic regulation in cats with uncomplicated diabetes mellitus.
• Reduction of glucose variability: May reduce glucose variability when combined with glargine insulin.
• Support of endogenous insulin secretion: May enhance glucose-dependent pancreatic insulin release in cats with remaining functional beta-cell mass.
• Potential diabetic remission support: Extended-release exenatide has been studied with glargine insulin in newly diagnosed diabetic cats; glucose variability was reduced, but remission rates and metabolic control were not statistically different from placebo at the end of the study.
• Weight management in obese diabetic cats: Reduced appetite and weight loss are reported adverse effects rather than an established indication; weight loss of 0.7 kg has been documented with the immediate-release form, while the extended-release form had a variable effect on weight and no effect on body condition score.
• Patients requiring multimodal diabetic control: Used as part of a multimodal plan alongside insulin, dietary carbohydrate control and glucose monitoring. Both published feline protocols combined exenatide with twice-daily glargine and a low-carbohydrate diet, and the extended-release study enrolled newly diagnosed cats.

Dosage (Reference)

Cat

Exenatide use in cats is extra-label and should be used only as an adjunct to insulin therapy, dietary carbohydrate control, and close diabetic monitoring. Published feline dosing protocols involve either immediate-release (IR) or extended-release (ER) formulations, which are not interchangeable.

Dog

The available veterinary monograph provides feline dosing protocols only; no canine treatment protocol is described. Routine canine use is not described in this source.

Warnings & Precautions

Exenatide should be used cautiously in cats because veterinary experience remains limited and most available data come from small feline studies or extrapolation from human medicine. It is intended as an adjunctive diabetic therapy and requires close monitoring during treatment.

• Not an insulin substitute: Exenatide cannot replace insulin in diabetic cats and should not be used alone for insulin-dependent diabetes or diabetic ketoacidosis.
• Renal disease: Use cautiously in cats with impaired renal function or a history of renal transplantation. Avoid use in severe or end-stage renal disease; monitor BUN and creatinine during therapy. Acute kidney injury has been reported in people taking exenatide.
• Gastrointestinal disease: Avoid exenatide in severe gastrointestinal disease. It delays gastric emptying in cats; in people, the immediate-release form should not be used with gastroparesis or inflammatory bowel disease.
• Pancreatitis risk: Use cautiously in cats with a history of pancreatitis or of drug-induced immune-mediated thrombocytopenia. If pancreatitis or drug-induced immune-mediated thrombocytopenia occurs during treatment, stop exenatide and do not restart it – either event precludes any further use of the drug.
• Hypoglycemia: The risk is low when exenatide is used alone but increases when it is combined with insulin or another hypoglycemic agent. Careful glucose monitoring and insulin dose adjustment may be required.
• Weight loss and reduced appetite: Monitor body weight and food intake closely; weight loss is a documented effect of the immediate-release form.
• Drug-induced thrombocytopenia: Drug-induced immune-mediated thrombocytopenia is an uncommon but significant concern in people. Monitor a CBC with platelet count as part of routine therapy monitoring.
• Injection technique: Administer subcutaneously only. Rotate injection sites regularly and monitor for local irritation or discomfort; the usual sites are the back of the neck and the shoulder area.
• Oral medication absorption: Slowed gastric emptying may delay absorption of oral drugs. Administer oral medications at least one hour before exenatide.
• Formulation differences: Immediate-release (IR) and extended-release (ER) products are not interchangeable and use different dosing schedules.
• Handling precautions: Exenatide is classified as a hazardous drug by NIOSH. Wear gloves and eye protection when preparing and administering the extended-release product, and wash hands thoroughly afterward.
• Pregnancy and nursing: Safety in breeding, pregnant or lactating cats has not been established, so the drug should only be used when the maternal benefit outweighs the potential risk to the offspring. Exenatide is unlikely to cross the placenta, but high doses of the immediate-release form caused skeletal abnormalities, cleft palate and reduced fetal and neonatal growth in mice and rabbits, and neonatal deaths occurred in mice given 6 micrograms/kg/day. The extended-release form reduced fetal growth and delayed ossification in rats. In mice, milk concentrations were 2.5% of maternal plasma; because exenatide is not absorbed orally, the risk to a nursing kitten is likely negligible.
• Absolute contraindications: Exenatide is contraindicated in a cat with known hypersensitivity to it or to any component of the formulation. The extended-release form is additionally contraindicated in people with medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2; it caused dose- and duration-dependent thyroid C-cell tumors in rats, and the US label carries that finding as a boxed warning.

Drug Interactions

Most clinically relevant interactions with exenatide involve altered blood glucose control, delayed absorption of oral medications, or masking of hypoglycemia signs. Concomitant use is not necessarily contraindicated; weigh the potential risks and perform additional monitoring when appropriate.

• Insulin (e.g., glargine): Concurrent use reduced glucose variability in the published feline study but increases the risk of hypoglycemia. Insulin dose reduction may be required with close glucose monitoring.
• Oral hypoglycemic agents: Additive glucose-lowering effects may occur, increasing the risk of hypoglycemia.
• Corticosteroids (e.g., prednisolone, dexamethasone): May diminish the hypoglycemic activity of exenatide.
• Sympathomimetic agents (e.g., epinephrine, phenylpropanolamine): Listed with the corticosteroids among the drug classes that may diminish the hypoglycemic activity of exenatide.
• Alpha-2 agonists (e.g., dexmedetomidine, xylazine): May cause transient hyperglycemia and reduce short-term diabetic control.
• Diuretics (e.g., furosemide): Furosemide and hydrochlorothiazide may diminish the glucose-lowering effect of exenatide.
• Thyroid hormones: Can elevate blood glucose levels in diabetic patients when thyroid hormone therapy is first initiated.
• Beta-blockers: Can have variable effects on glycemic control and can mask the clinical signs of hypoglycemia, which complicates diabetic monitoring.
• Clonidine / Reserpine: May also mask signs associated with hypoglycemia.
• Fluoroquinolones: Ciprofloxacin, enrofloxacin and pradofloxacin may potentiate the glucose-lowering effect of exenatide, increasing the risk of hypoglycemia.
• Delayed oral drug absorption: Because exenatide slows gastric emptying, absorption of concurrent oral medications may be delayed. Administer oral medications at least one hour before exenatide.
• Warfarin / anticoagulants: Concurrent use with warfarin may prolong prothrombin time.
• Digoxin: Peak digoxin concentration may be delayed and reduced, although overall steady-state exposure is unchanged.
• Other drugs that increase the risk of hypoglycemia: Anabolic steroids, ACE inhibitors, angiotensin II receptor blockers, disopyramide, fenofibrate, fluoxetine, monoamine oxidase inhibitors including amitraz and selegiline, pentoxifylline, salicylates, somatostatin derivatives and sulfonamides may all potentiate the glucose-lowering effect of exenatide.
• Other drugs that reduce diabetic control: Beta-adrenergic receptor agonists, cyclosporine, danazol, diazoxide, estrogens, isoniazid, leuprolide, niacin, phenothiazines and progestins may all diminish the glucose-lowering effect of exenatide.

Side Effects & Overdose

Side Effects

Gastrointestinal effects in cats include diarrhea, vomiting and loss of appetite; nausea, vomiting and lack of appetite are described as common side effects. Significant or prolonged changes in appetite, abnormal feces or weight loss should prompt reassessment of therapy.

• Nausea: Reported as a common side effect.
• Vomiting: One of the reported gastrointestinal effects in cats.
• Diarrhea / soft stool: Gastrointestinal upset may occur in some cats.
• Reduced appetite (anorexia/hyporexia): Appetite suppression is relatively common and should be monitored carefully in diabetic cats.
• Weight loss: Documented at about 0.7 kg in healthy, obese and diabetic cats given the immediate-release form; the extended-release form had a variable effect on weight and no effect on body condition score.
• Hypoglycemia: Unlikely when used alone, but the risk rises when combined with insulin or other glucose-lowering drugs: subclinical hypoglycemia occurred in 63% of diabetic cats given the immediate-release form with glargine, although rates with the extended-release form were similar to glargine alone.
• Lethargy / increased sleeping: Reduced activity has been observed in some treated cats.
• Behavioral changes: Hiding or injection-related irritability may occur in some individuals.
• Injection site reactions: Common in people but not reported in cats with either formulation.
• Rare serious reactions: In people, pancreatitis and drug-induced immune-mediated thrombocytopenia are uncommon but significant concerns. Exenatide-induced pancreatitis or increased feline pancreatic lipase has not been identified in cats, although feline exposure remains limited.
• Antibody development: Antibodies to exenatide developed in 44% to 49% of treated people. Most were low-titer and did not affect glycemic control, but 6% had high titers with an attenuated response.
• Hypersensitivity reactions: In people, severe reactions such as angioedema and anaphylaxis are rare, while milder reactions such as rash, urticaria and pruritus are more common.

Overdose

Exenatide overdose is expected to cause exaggerated pharmacologic effects, primarily gastrointestinal upset and hypoglycemia. Duration may depend on formulation used, with extended-release products potentially causing prolonged effects.

• Severe nausea and vomiting: Reported effects of an exenatide overdose, together with hypoglycemia.
• Marked Anorexia : Refusal to eat may lead to dehydration or worsening diabetic instability.
• Hypoglycemia: May occur after an exenatide overdose; during therapeutic use it is unlikely unless exenatide is combined with insulin or another glucose-lowering drug.
• Reduced Activity: Observed in cats during treatment rather than reported as an effect of overdose.
• Prolonged signs with ER products: Signs from an immediate-release overdose are expected to be short-lived, whereas an extended-release overdose could have effects for many weeks.
• Management: Treatment is supportive and directed by the clinical signs. For a suspected overdose, consult one of the 24-hour poison consultation centers that specialize in veterinary patients; for repeated or unexplained hypoglycemia, involve a veterinary emergency and critical care or endocrinology specialist.

Key Notes

Practical clinical points that may help optimize the safe and effective use of exenatide in feline diabetic patients:

• Best candidate selection: Exenatide is described for uncomplicated feline diabetes, and efficacy depends on an adequate mass of functional pancreatic beta cells; the extended-release study enrolled newly diagnosed cats.
• Clinical goals: Success should be judged by improved thirst, urination, appetite balance, body condition, and home behavior—not blood glucose numbers alone.
• Consistency matters: Maintain a predictable feeding routine, insulin schedule, and injection timing to improve interpretation of glucose trends.
• Body condition tracking: Monitor body weight regularly; weight loss may reflect diabetic control or an adverse effect of the immediate-release form.
• Owner training: Caregivers should be trained in injection technique, home glucose monitoring and recognition of hypoglycemia.
• Expect variability: Individual response can differ widely; some cats show meaningful improvement while others gain little measurable benefit.
• Use as part of a system: Diet, insulin treatment, monitoring and management of diseases that cause insulin resistance are all components of diabetic care.
• Available products: No veterinary-labeled product exists. The immediate-release solution is 250 µg/mL in prefilled pens that deliver 60 doses of either 5 µg (1.2 mL total) or 10 µg (2.4 mL total), sold as Byetta with needles supplied separately; the pens themselves contain 300 µg/1.2 mL or 600 µg/2.4 mL. The extended-release product is a 2 mg single-dose vial supplied in a kit with a prefilled syringe of 0.65 mL diluent, four vial-diluent pairs per unit, sold as Bydureon. A 2 mg pen and the Bydureon BCise autoinjector also exist but are not practical for feline doses.
• Pharmacokinetics in cats: In healthy cats, immediate-release exenatide peaked at 45 minutes and was no longer significantly different from baseline after 90 minutes. Extended-release exenatide was measurable within 15 minutes, had peaks at one hour and at four weeks, and was no longer significantly different from baseline at six weeks. In people, exenatide undergoes renal elimination by glomerular filtration and proteolytic degradation; the immediate- and extended-release half-lives are 2.4 hours and 14 days.
• Laboratory monitoring: Monitor feline pancreatic lipase immunoreactivity, BUN, creatinine and a CBC with platelet count; check injection sites for local reactions; and watch the response to any oral medication given alongside exenatide, since gastric emptying is slowed.
• When to run a glucose curve: A blood glucose curve is worth running after the first dose of a new insulin type, 7 to 14 days after starting insulin or changing the dose, at least every three months even when diabetes is well controlled, whenever clinical signs return, and whenever hypoglycemia is suspected.
• Interpreting the monitoring tools: Flash glucose monitoring systems are easy to apply and give useful information in hospital or at home. Urine glucose is typically only helpful for documenting prolonged hypoglycemia, or persistently negative glucose when monitoring for remission, because even a well-controlled diabetic cat may be intermittently glucosuric through the day. Fructosamine or glycosylated hemoglobin can be measured where available and warranted.
• Storage and in-use life: Store unused product refrigerated at 2°C to 8°C (36°F to 46°F), protected from light, and discard it if it has been frozen. Once in use, the immediate-release pen may be kept between 2°C and 25°C (36°F to 77°F) and is discarded 30 days after first use; do not store it with a needle attached, as solution may leak and air bubbles form. The extended-release product may be held unmixed at room temperature for no more than four weeks.
• Chemistry and other names: Exenatide is a synthetic 39-amino-acid peptide first identified in the saliva of the Gila monster; it has a molecular weight of 4187 and shares 53% of its sequence with mammalian GLP-1. It is also known as AC 2993, LY2148568 and exendin-4.